Cargando…

Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors with a 5‐year survival rate of less than 10% and a median survival of 6 months after diagnosis. Numerous targeted agents have been developed and evaluated to improve the survival benefit in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, An‐Dong, Zhou, Jie, Bi, Xiao‐Yang, Hou, Guo‐Qing, Li, Shawn Shun‐Cheng, Chen, Qing, Xu, Hui, Cao, Xuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908048/ https://www.ncbi.nlm.nih.gov/pubmed/33783993 http://dx.doi.org/10.1002/ctm2.337

Ejemplares similares

Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis
por: Wang, Meng, et al.
Publicado: (2022)

(Arg)(9)-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling
por: Liu, An-dong, et al.
Publicado: (2018)

Identification and characterization of a large family of superbinding bacterial SH2 domains
por: Kaneko, Tomonori, et al.
Publicado: (2018)

Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma
por: Li, Q., et al.
Publicado: (2020)

A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma
por: Clawson, Gary A., et al.
Publicado: (2017)

Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma
por: Champanhac, Carole, et al.
Publicado: (2015)

Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
por: Sato, Norihiro, et al.
Publicado: (2016)

DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition
por: Wu, Xiaoqiu, et al.
Publicado: (2015)

Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)

Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
por: Cruz-Monserrate, Zobeida, et al.
Publicado: (2014)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Targeting dendritic cells in pancreatic ductal adenocarcinoma
por: Deicher, Anton, et al.
Publicado: (2018)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
por: Liu, Jinlu, et al.
Publicado: (2023)

Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo
por: Yoon, Sorah, et al.
Publicado: (2016)

Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma
por: Kelly, Kimberly A, et al.
Publicado: (2008)

Super-enhancers: novel target for pancreatic ductal adenocarcinoma
por: Ghosh, Chandrayee, et al.
Publicado: (2019)

Splice variants as novel targets in pancreatic ductal adenocarcinoma
por: Wang, Jun, et al.
Publicado: (2017)

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2020)

Key drug-targeting genes in pancreatic ductal adenocarcinoma
por: Sakharkar, Meena Kishore, et al.
Publicado: (2021)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Heparanase regulates in vitro VEGF-C expression and its clinical significance to pancreatic ductal cell adenocarcinoma
por: LV, BIN, et al.
Publicado: (2016)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

ID1 marks the tumorigenesis of pancreatic ductal adenocarcinoma in mouse and human
por: Tang, Yuanxin, et al.
Publicado: (2022)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
por: Rai, Vikrant, et al.
Publicado: (2020)

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
por: Wu, Yang, et al.
Publicado: (2021)

Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Skorupan, Nebojsa, et al.
Publicado: (2022)

Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
por: Kung, Heng‐Chung, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Oligoadenylate synthetases-like is a prognostic biomarker and therapeutic target in pancreatic ductal adenocarcinoma
por: Chen, Shihong, et al.
Publicado: (2022)

Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
por: Xu, Yongfeng, et al.
Publicado: (2022)

Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
por: Creeden, Justin F., et al.
Publicado: (2020)

Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
por: Tong, Yexin, et al.
Publicado: (2022)

Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis
por: Wang, Jin-Dao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rqtuh929hsb1c2lb4k0mrcav1u